IT WAS A DISAPPOINTING TRIP to the public equity markets for Dynacare, Inc. last month. The lab company raised only $50 million in its initial public offering (IPO). Dynacare had hoped to harvest as much as $89 million from this IPO. Plans were to sell seven million shares at about $13 per share. But after […]
To access this post, you must purchase The Dark Report.